

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

JAVITT, Daniel, et al.

Continuation Appln. of 09/320,446

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: January 30, 2002

For: GLYCINE SITE FULL AGONIST FOR TREATING A PSYCHOSIS



INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

Applicant is not submitting duplicate copies of these references but requests that they be listed on the face of any patent granted on the above application. Since they were submitted in parent USSN 09/320,446. (See 37 CFR §1.98(d)).


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a

INFORMATION DISCLOSURE STATEMENT
CONTINUATION OF APPLN. OF 09/320,446

request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


Respectfully submitted,



Louis Gubinsky
Registration No. 24,835

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: January 31, 2002

Form PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. A8301	Serial No. Continuation of 09/320,446		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Dr. Daniel C. JAVITT			
Filing Date: 1/31/02				Group: Unassigned			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
		4,904,681	2/1990	Cordi et al.			11002 U.S. PTO 10/059362  01/31/02
		5,260,324	11/1993	Cordi et al.			
		5,187,171	2/1993	Cordi et al.			
		5,068,412	11/1991	Ohfune e t al.			
		5,086,072	2/1992	Trullas, et al.			
		5,179,085	1/1993	Bigge et al.			
		5,428,069	6/1995	Skolnick et al.			
FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub-class	Translation Yes/No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.							

Form PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. A8301		Serial No. Continuation of 09/320,446	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Dr. Daniel C. JAVITT			
				Filing Date: 1/31/02		Group: Unassigned	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub-class	Translation Yes/No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486.					
		Debler EA, Lajtha A (1987): High-affinity transport of n-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamic acid in synaptosomal (P2) tissue: a kinetic and substrate specificity analysis. J Neurochem 48:1851-6.					
		D'Souza DC, Charney D, Krystal J (1995): Glycine site agonists of the NMDA receptor: a review. CNS Drug Revs 1:227-260.					
		Hashimoto A, Oka T (1997): Free D-aspartate and D-serine in the mammalian brain and periphery. Prog. Neurobiol 52:325-353.					
		Heresco-Levy U, Javitt DC, Irmilov M, Mordel C, Horowitz A, Kelly D (1996): Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.					
		Javitt DC, Sershen H, Hashim A, Lajtha A (1997): Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake antagonist glycyldodecylamide. Neuropsychopharmacol 17:202-204.					
		Javitt DC, Frusciante MJ. (1997): Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacol. 129: 96-98.					
		Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.					
		Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-8.					
		Javitt DC, Zukin SR (1989): Interaction of [³ H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain. Proc. Nat. Acad. Sci. USA 86:740-744.					
		Javitt DC (1987): Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hill J Psychiat 9:12-35.					
		Kleckner NW, Dingledine R (1988): Requirement for glycine in the activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835-837.					
		Leiderman E, Zylberman I, Javitt DC, Zukin SR, Cooper TB. Effect of high-dose oral glycine on serum levels and negative symptoms in schizophrenia. Biol. Psychiatry, in press.					
		Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N (1993): Cloning and expression of spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem 268:22802-8.					

INFORMATION DISCLOSURE STATEMENT

	Matsui T, Sekiguchi M, Hashimoto A, Tomita V, Nishikawa T, Wada K (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem. 65:454-458.
	McBain CJ, Kleckner NW, Wyrick S, Dingledine R (1989): Structural requirements for the glycine coagonist site of N-methyl-D-aspartate receptors expressed in <i>Xenopus</i> oocytes. Mol Pharmacol 36:556-565.
	Reynold IJ, Murphy SN, Miller RJ (1987): 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc. Natl. Acad. Sci. USA 84:7744-7748.
	Schell MJ, Molliver ME, Snyder SH (1995). D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. USA 92:3948-3952.
	Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL (1992): Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-35.
	Supplisson S, Bergman C (1997): Control of NMDA receptor activation by a glycine transporter co-expressed in <i>Xenopus</i> oocytes. J Neurosci 17:4580-90.
	Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1991): Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Res 563:281-284.
	Tanii Y, Hishikawa T, Hashimoto A, Takahashi K (1994): Stereoselective antagonism by enantiomers of alanine an d-serine of phencyclidine-induced hyperactivity, stereotypy and ataxia. J. Pharmacol. Exp. Ther. 269:1040-1048.
	Tsai G, Yang P, Chung L-C, Lange N, Coyle JT (1998): D-serine in the treatment of schizophrenia. Biol. Psychiatry 44:1081-1089.
	Wood PL (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10
	Wong EH, Knight AR, Ransom R (1987) Glycine modulates [3H]MK-801 binding to the NMDA receptor in rat brain. Eur J Pharmacol 142:487-8.
	Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J (1995): Glycine transporters are differentially expressed among CNS cells. J Neurosci 15:3952-69
	Michael J. Schell, et al. "D-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors" The Journal of Neuroscience, March 1, 1998, 17(5): 1604-1615

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.